Kevin Kotler’s Broadfin Capital Opened Huge Biodelivery Sciences International Inc Position

February 14, 2018 - By Nellie Frank

 Kevin Kotler's Broadfin Capital Opened Huge Biodelivery Sciences International Inc Position

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.67, from 1 in 2017Q2. It increased, as 8 investors sold BioDelivery Sciences International, Inc. shares while 7 reduced holdings. 6 funds opened positions while 19 raised stakes. 20.34 million shares or 6.83% more from 19.04 million shares in 2017Q2 were reported.

Citadel Advsrs Ltd Liability invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). California Employees Retirement Systems has 259,400 shares. Manufacturers Life Ins The stated it has 2,228 shares or 0% of all its holdings. Sigma Planning holds 14,472 shares. Broadfin Ltd holds 1.92% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 4.41 million shares. Blair William Communications Il has 1.50M shares for 0.03% of their portfolio. Northern Corporation holds 156,626 shares. Moreover, Jpmorgan Chase Company has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Jacobs Levy Equity Mgmt invested in 219,869 shares or 0.01% of the stock. Hikari Power Limited holds 0.23% or 601,285 shares. 408,667 were accumulated by Gsa Cap Prtnrs Ltd Liability Partnership. 31,500 are held by Price T Rowe Associates Md. Royal Retail Bank Of Canada holds 1,402 shares. Cutter And Brokerage owns 38,660 shares. Valley Natl Advisers accumulated 37,715 shares or 0.04% of the stock.

Since September 14, 2017, it had 0 buys, and 2 selling transactions for $2.51 million activity.

The New Kevin Kotler’s Broadfin Capital Holding in Biodelivery Sciences International Inc

Broadfin Capital reported SC 13G/A form with the SEC for Biodelivery Sciences International Inc. Access it here: 000091957418001175. As reported by Kevin Kotler’s Broadfin Capital, the filler owns 8.29% or 4,634,119 shares of the Health Care–company.

Biodelivery Sciences International Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Kevin Kotler’s Broadfin Capital’s positive view for Biodelivery Sciences International Inc. For a hedge fund managing $1.26 billion in assets and having 10+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Kevin Kotler’s Broadfin Capital’s portfolio is in the sector.

Biodelivery Sciences International Inc Institutional Sentiment

Filings show 125 investors own Biodelivery Sciences International Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 8980338. 50452610 were owned by these investors. 16 funds opened new Biodelivery Sciences International Inc stakes, 55 increased positions. There were 31 that closed positions and 35 reduced them.

Kevin Kotler Broadfin Capital Llc is an investor bullish on Biodelivery Sciences International Inc, owning 4744060 shares as of Q3 2015 for 1.47% of its portfolio. 1492 Capital Management Llc owns 497469 shares or 1.97% of its portfolio. NC Franklin Street Advisors Inc have 0.22% of its portfolio for 199375 shares. Further, Foresite Capital Management I Llc reported stake worth 29.31% of its portfolio. The NJ Condor Capital Management owns 12090 shares. Biodelivery Sciences International Inc is 0.02% of its portfolio.

Business Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

SEC Form 13G.

Kevin Kotler’s Broadfin Capital website.

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on March, 16. They expect $-0.23 EPS, up 20.69 % or $0.06 from last year’s $-0.29 per share. After $-0.21 actual EPS reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts 9.52 % negative EPS growth.

The stock increased 4.35% or $0.1 during the last trading session, reaching $2.4. About 668,389 shares traded or 13.12% up from the average. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 24.37% since February 14, 2017 and is uptrending. It has outperformed by 7.67% the S&P500.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $134.12 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 23.76 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 7 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery Sciences International has $14 highest and $300 lowest target. $5.93’s average target is 147.08% above currents $2.4 stock price. BioDelivery Sciences International had 32 analyst reports since August 16, 2015 according to SRatingsIntel. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Monday, July 24. H.C. Wainwright has “Buy” rating and $400 target. Piper Jaffray maintained it with “Buy” rating and $4.0 target in Friday, October 20 report. The rating was maintained by H.C. Wainwright on Friday, October 13 with “Buy”. On Friday, May 26 the stock rating was initiated by H.C. Wainwright with “Buy”. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) earned “Buy” rating by Roth Capital on Friday, March 11. H.C. Wainwright initiated it with “Buy” rating and $5.0 target in Friday, September 8 report. Janney Capital upgraded the shares of BDSI in report on Friday, September 23 to “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Monday, July 10. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, August 10. H.C. Wainwright maintained it with “Buy” rating and $5.0 target in Tuesday, February 6 report.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Prnewswire.com which released: “BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva” on October 12, 2017, also Globenewswire.com with their article: “BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical” published on December 14, 2017, Seekingalpha.com published: “Assessing BioDelivery Sciences International” on June 27, 2017. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Prnewswire.com and their article: “BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference” published on November 16, 2017 as well as Globenewswire.com‘s news article titled: “BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement …” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.